Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A
作者:Victoria A. Steadman、Simon B. Pettit、Karine G. Poullennec、Linos Lazarides、Andrew J. Keats、David K. Dean、Steven J. Stanway、Carol A. Austin、Jonathan A. Sanvoisin、Gregory M. Watt、Hans G. Fliri、Albert C. Liclican、Debi Jin、Melanie H. Wong、Stephanie A. Leavitt、Yu-Jen Lee、Yang Tian、Christian R. Frey、Todd C. Appleby、Uli Schmitz、Petr Jansa、Richard L. Mackman、Brian E. Schultz
DOI:10.1021/acs.jmedchem.6b01329
日期:2017.2.9
Cyclophilin inhibition has been a target for the treatment of hepatitis C and other diseases, but the generation of potent, drug-like molecules through chemical synthesis has been challenging. In this study, a set of macrocyclic cyclophilin inhibitors was synthesized based on the core structure of the natural product sanglifehrin A. Initial compound optimization identified the valine-m-tyrosine-piperazic
抑制亲环蛋白一直是治疗丙型肝炎和其他疾病的目标,但是通过化学合成产生有效的类药物分子一直具有挑战性。在这项研究中,一组大环亲环蛋白抑制剂的合成基于天然产物的萨菲菌素识别的缬氨酸A.初始化合物优化的核心结构米-酪氨酸-六氢哒嗪酸三肽(Val-米在萨菲菌素-Tyr-PIP)芯,在C14和C15立构,和的羟基米-酪氨酸(米-Tyr)残留物是复合效价的关键因素。用苯乙烯基取代sanglifehrin的C18–C21二烯单元会产生有效的化合物,这些化合物表现出新颖的结合模式,其中苯乙烯部分与亲环蛋白A(Cyp A)的Arg55和m -Tyr进行π堆积相互作用将残留物移入溶剂中。该观察结果允许进一步简化支架以产生新的先导化合物,以寻找口服生物可利用的亲环蛋白抑制剂。